Kangfang Biotech (09926) announced interim results. Revenue increased 27.92% year-on-year to 1.806 billion yuan

According to the Zhitong Finance App, Kang Fang Biotech (09926) announced interim results for the six months ended June 30, 2026. The group obtained revenue of 1,806 billion yuan (RMB, same below), an increase of 27.92%; gross profit of 1.34 billion yuan, an increase of 19.62%; and R&D expenditure of 783 million yuan, an increase of 7.12% over the previous year. The owner of the parent company should have accounted for a loss of 424 million yuan, or 0.46 yuan per share.

According to the announcement, the company's commercial sales revenue was about 1,803 billion yuan, up 28.65% year on year from 1,402 million yuan in the same period last year, mainly due to important sales contributions from the two cancer immunostimulatory double antagonists Ketanib® (Cardonil, PD-1/CTLA-4) and Edafon® (Evarosi, PD-1/VEGF). Several of the company's other commercial products also contributed in part to sales growth, including Ixinin® (Inusi, PCSK9) and IDARO® (IL-12/IL-23).

The company's first batch of five independent commercialized innovative drugs. A total of 12 approved indications have been included in the latest edition of the National Health Insurance Catalogue, and hospital admission has also achieved broad coverage and deep penetration. As of June 30, 2026, the company has formed a specialized and systematic sales team of more than 1,600 people, covering the two core areas of oncology and specialty drugs. The company actively practices “patient-centered” “academic marketing” and broadly explores diversified channels such as commercial insurance to drive the existing product portfolio to achieve sustainable growth and maximize collaborative advantages.

In addition, during the reporting period, the company also received commercial licensing revenue from the two product partners, totaling 2.5 million yuan.